KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD) : executive summary
Torres, V.E. (Mayo Clinic)
Ahn, C. (Seoul National University)
Barten, T.R.M. (Radboud University Medical Center)
Brosnahan, G. (University of Colorado)
Cadnapaphornchai, M.A. (University of Pennsylvania Perelman School of Medicine)
Chapman, A.B. (University of Chicago)
Cornec-Le Gall, Emilie (Inserm UMR1078)
Drenth, J.P.H. (Radboud University Medical Center)
Gansevoort, R.T. (University of Groningen)
Harris, P.C. (Mayo Clinic)
Harris, T. (Polycystic Kidney Disease Charity UK)
Horie, S. (Juntendo University)
Liebau, M.C. (University Hospital Cologne (Colònia, Alemanya))
Liew, M. (Patient partner)
Mallett, Andrew J.. (Townsville University Hospital)
Mei, C. (Changzheng Hospital)
Mekahli, D. (University Hospital Leuven)
Odland, D. (PKD Foundation)
Ong, Albert C M (University of Sheffield)
Onuchic, L.F. (Universidade de São Paulo)
Pei, Y.P.C. (University of Toronto)
Perrone, R.D. (Tufts University School of Medicine)
Rangan, G.K. (The University of Sydney)
Rayner, B. (University of Cape Town)
Torra Balcells, Roser (Institut de Recerca Sant Pau)
Balk, E.M. (Brown University School of Public Health)
Gordon, C.E. (Brown University School of Public Health)
Earley, A. (KDIGO)
Mustafa, R.A. (University of Kansas)
Devuyst, Olivier (UCLouvain Medical School)
Universitat Autònoma de Barcelona

Date:	2025
Abstract:	The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations. The development of this guideline followed an explicit process of evidence review and appraisal, based on a rigorous, formal systematic literature review. The strength of recommendations follows the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points serving to direct clinical care or activities relating to areas for which a systematic review was not conducted. Limitations of the evidence are discussed. Research recommendations to address gaps in knowledge, and implications for policy and payment, are provided. The guideline targets a broad audience of healthcare providers, people living with ADPKD, and stakeholders involved in the various aspects of ADPKD care.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	ADPKD ; Evidence-based ; Guideline ; Monogenic disease ; Nomenclature
Published in:	Kidney International, Vol. 107 Núm. 2 (february 2025) , p. 234-254, ISSN 1523-1755

DOI: 10.1016/j.kint.2024.07.010
PMID: 39848746

22 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles